Finally, to investigate if BIM accumulation also occurs in patients, we performed immunohistochemistry (IHC) analyses of formalin-fixed and paraffin-embedded (FFPE) ALK+ NSCLC samples before and during treatment with the ALK inhibitor lorlatinib. This evidence concerns the gene ALK and non-small cell lung carcinoma.